News and updates

January 3, 2020

PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse   IRVINE, CALIF., U.S. and Amsterdam – 3 January 2020 – Agendia Inc., a world leader in precision oncology for breast cancer, announces that one of the largest healthcare insurers in Germany, Techniker Krankenkasse, has joined the Selective…

December 23, 2019

PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, December 12, 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today new data comparing genomic profiling results for patients under the age of 50 with early-stage breast…

November 19, 2019

PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer patients   IRVINE, CALIF. – 19 November 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that five abstracts featuring data…

September 28, 2019

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at the European Society for Medical Oncology (ESMO) Congress 2019, taking place from September 27 to October 1 in Barcelona, Spain.…